These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 2126536)

  • 1. Ferrite particles (AMI25). Influence of cirrhosis and chemotherapy on magnetic resonance imaging of metastasis.
    Clement O; Schouman-Claeys E; Frija G
    Invest Radiol; 1990 Sep; 25 Suppl 1():S61-2. PubMed ID: 2126536
    [No Abstract]   [Full Text] [Related]  

  • 2. Liver tumors in cirrhosis: experimental study with SPIO-enhanced MR imaging.
    Clement O; Frija G; Chambon C; Schouman-Clayes E; Mosnier JF; Poupon MF; Balkau B
    Radiology; 1991 Jul; 180(1):31-6. PubMed ID: 2052718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver-specific contrast agents for MRI.
    Stark DD; Elizondo G; Fretz CJ
    Invest Radiol; 1990 Sep; 25 Suppl 1():S58. PubMed ID: 2126535
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy and safety of liver-specific MRI contrast agents in rats with hepatitis and cirrhosis.
    Kato N; Takahashi M; Ihara S; Tsujimoto T; Miyazawa T
    Acad Radiol; 1998 Apr; 5 Suppl 1():S83-5. PubMed ID: 9561051
    [No Abstract]   [Full Text] [Related]  

  • 5. Superparamagnetic iron oxide-enhanced magnetic resonance imaging of experimental liver tumors after mitomycin C administration.
    Clement O; Frija G; Chambon C; Schouman-Clayes E
    Invest Radiol; 1992 Mar; 27(3):230-5. PubMed ID: 1551774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic and hemodynamic safety of two superparamagnetic agents, Endorem and Sinerem, in cirrhotic rats.
    Bonnemain B
    Acad Radiol; 1998 Apr; 5 Suppl 1():S151-3; discussion S156. PubMed ID: 9561067
    [No Abstract]   [Full Text] [Related]  

  • 7. [Magnet resonance spectroscopy of tumor-bearing rat livers: magnetite particles as an aid in volume selection].
    Römer T; Gewiese B; Stiller D; Plötz M; Lawaczeck R; Wolf KJ
    Rofo; 1990 Jul; 153(1):79-84. PubMed ID: 2166318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Receptor imaging: application to MR imaging of liver cancer.
    Reimer P; Weissleder R; Lee AS; Wittenberg J; Brady TJ
    Radiology; 1990 Dec; 177(3):729-34. PubMed ID: 2243978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Magnetic resonance lymphography. Enhancement patterns using superparamagnetic nanoparticles.
    Clément O; Guimaraes R; de Kerviler E; Frija G
    Invest Radiol; 1994 Jun; 29 Suppl 2():S226-8. PubMed ID: 7928239
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacokinetics of superparamagnetic iron-oxide MR contrast agents in the rat.
    Majumdar S; Zoghbi SS; Gore JC
    Invest Radiol; 1990 Jul; 25(7):771-7. PubMed ID: 2391194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MR enhancement of hepatoma by superparamagnetic iron oxide (SPIO) particles.
    Yamamoto H; Yamashita Y; Yoshimatsu S; Baba Y; Takahashi M
    J Comput Assist Tomogr; 1995; 19(4):665-7. PubMed ID: 7622710
    [No Abstract]   [Full Text] [Related]  

  • 12. Iron oxide nanoparticles for use as an MRI contrast agent: pharmacokinetics and metabolism.
    Pouliquen D; Le Jeune JJ; Perdrisot R; Ermias A; Jallet P
    Magn Reson Imaging; 1991; 9(3):275-83. PubMed ID: 1881245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Definition of liver tumors in the presence of diffuse liver disease: comparison of findings at MR imaging with positive and negative contrast agents.
    Kuwatsuru R; Brasch RC; Mühler A; Mathur A; Vexler VS; Rosenau W; Mintorovitch J; Berthezene Y; Cohen F; Shames DM
    Radiology; 1997 Jan; 202(1):131-8. PubMed ID: 8988202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experimental hepatocellular carcinoma: MR receptor imaging.
    Reimer P; Weissleder R; Brady TJ; Yeager AE; Baldwin BH; Tennant BC; Wittenberg J
    Radiology; 1991 Sep; 180(3):641-5. PubMed ID: 1871273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct visualization of peritumoral rims.
    Kruskal JB
    AJR Am J Roentgenol; 1997 Aug; 169(2):595-6. PubMed ID: 9242784
    [No Abstract]   [Full Text] [Related]  

  • 16. [Detection of liver lesions: magnetic resonance tomography using superparamagnetic iron particles (AMI-25, endorem) as a contrast medium in comparison with ultrasound diagnosis, computerized tomography and CT portography].
    Pleger B; Beyer HK; Laufer U
    Rontgenpraxis; 2001; 53(6):245-9. PubMed ID: 11402872
    [No Abstract]   [Full Text] [Related]  

  • 17. Pitfalls in employing superparamagnetic iron oxide particles for stem cell labelling and in vivo MRI tracking.
    Wang YX; Wang HH; Au DW; Zou BS; Teng LS
    Br J Radiol; 2008 Dec; 81(972):987-8. PubMed ID: 19029055
    [No Abstract]   [Full Text] [Related]  

  • 18. Overview of contrast enhancement with iron oxides.
    Frija G; Clément O; de Kerviler E
    Invest Radiol; 1994 Jun; 29 Suppl 2():S75-7. PubMed ID: 7928276
    [No Abstract]   [Full Text] [Related]  

  • 19. Sensitive physiologic imaging with contrast-enhanced magnetic resonance imaging.
    Litt L
    Anesthesiology; 1998 Apr; 88(4):847-50. PubMed ID: 9579490
    [No Abstract]   [Full Text] [Related]  

  • 20. Real enhancement or merely increased contrast?
    Chen JH
    AJR Am J Roentgenol; 1997 Jan; 168(1):279-80. PubMed ID: 8976963
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.